![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
|
Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Caption: Rameen Beroukhim, M.D., Ph.D., and his colleagues at Dana-Farber Cancer Institute and Broad Institute scientists report that large-scale genomic sequencing has revealed two DNA mutations that appear to drive about 15 percent of meningiomas. Experimental drugs that inhibit these mutant gene pathways are in clinical trials and have shown promising activity, suggesting that targeted therapies already in development or use may work against these specific meningiomas.
Credit: Sam Ogden
Usage Restrictions: None
Related news release: Genomic sequencing identifies mutant 'drivers' of common brain tumor
|